New pharmacotherapies for pulmonary hypertension: where do they fit in?
Curr Hypertens Rep
; 16(12): 496, 2014 Dec.
Article
em En
| MEDLINE
| ID: mdl-25304107
ABSTRACT
Pulmonary arterial hypertension (PAH) is a rare, progressively worsening disease characterized by dysfunction among endothelial and smooth muscle cells within the pulmonary vasculature with a resultant increase in pulmonary vascular resistance, right ventricular maladaptation and failure, and ultimately early death. The three major therapeutic classes of medications available to treat PAH act as either prostacyclin analogs or endothelin receptor antagonists (ERAs) or by increasing local nitric oxide (NO) levels by means of phosphodiesterase type 5 inhibitors. Several recent trials have investigated the use of oral prostanoid therapy, next-generation ERAs, and soluble guanylate cyclase stimulators (to increase NO levels) as well as novel formulations of pre-existing therapies. The goal of this manuscript is to briefly review established therapies and then discuss recent developments and practical considerations in each of the major drug classes.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Papel do Médico
/
Resistência Vascular
/
Antagonistas dos Receptores de Endotelina
/
Hipertensão Pulmonar
/
Anti-Hipertensivos
/
Óxido Nítrico
Limite:
Humans
Idioma:
En
Revista:
Curr Hypertens Rep
Assunto da revista:
ANGIOLOGIA
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Estados Unidos